Belén Blanco
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Belén Blanco has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Concepción Rodríguez-Serrano
Department of Hematology, Hospital Universitario de Salamanca/Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain
2 shared publications- Mercedes Sánchez-Barba
Department of Statistics, Faculty of Medicine, University of Salamanca, 37007 Salamanca, Spain
2 shared publications Carmen Herrero-Sanchez
1 shared publicationCarmen Herrero-Sánchez
Department of Hematology, Hospital Universitario de Salamanca/Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain
1 shared publicationConcepción Rodríguez‐Serrano
Servicio de Hematología, Hospital Universitario de Salamanca - Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain
1 shared publicationConsuelo Canizo
1 shared publication
Latest Publications
- 1 June 2016
- Published by Wiley in European Journal of Haematology
- Vol. 97 (6) , 528-537
Immunomodulatory effects of bone marrow versus adipose tissue‐derived mesenchymal stromal cells on NK cells: implications in the transplantation setting
Introduction: The ability of mesenchymal stromal cells (MSC) to suppress T‐cell function has prompted their therapeutic use for graft‐versus‐host disease (GVHD) control. However, as MSC also modulate the activity of NK cells, which play an important role in graft‐versus‐leukemia (GVL) reaction, their administration could hamper this beneficial effect of allogeneic hematopoietic stem cell transplantation. MSC can be expanded from several sources, especially bone marrow and fat, but it is not well established if the cell source makes a difference in their immunoregulatory capacity.Objective: The aim of this study was to compare the immunomodulatory effect of MSC derived from bone marrow (BM‐CSM) or adipose tissue (AT‐MSC) on NK cells, to determine whether the use of MSC from one or the other origin could be more favorable to preserve NK cell activity and, therefore, GVL.Methods: Human NK cells were stimulated with IL‐15 in the presence of BM‐MSC or AT‐MSC. The effect of both MSC populations on NK cell proliferation, cell cycle progression, and CD56 expression was analyzed by flow cytometry. Cytokine secretion was measured by ELISA, and cytotoxic activity was assessed by calcein release assays.Results: Although both BM‐MSC and AT‐MSC induced a similar inhibition of NK cell proliferation, only BM‐MSC decreased significantly NK cell cytotoxic activity and showed a trend for a higher reduction of IFN‐γ secretion.Conclusion: These results suggest that, in the context of GVHD inhibition, the use of AT‐MSC rather than BM‐MSC could further preserve NK cell activity and, thus, favor GVL.
- 1 June 2016
- Published by Wiley in European Journal of Haematology
- Vol. 97 (6) , 528-537
Immunomodulatory effects of bone marrow versus adipose tissue‐derived mesenchymal stromal cells on NK cells: implications in the transplantation setting
Introduction: The ability of mesenchymal stromal cells (MSC) to suppress T‐cell function has prompted their therapeutic use for graft‐versus‐host disease (GVHD) control. However, as MSC also modulate the activity of NK cells, which play an important role in graft‐versus‐leukemia (GVL) reaction, their administration could hamper this beneficial effect of allogeneic hematopoietic stem cell transplantation. MSC can be expanded from several sources, especially bone marrow and fat, but it is not well established if the cell source makes a difference in their immunoregulatory capacity.Objective: The aim of this study was to compare the immunomodulatory effect of MSC derived from bone marrow (BM‐CSM) or adipose tissue (AT‐MSC) on NK cells, to determine whether the use of MSC from one or the other origin could be more favorable to preserve NK cell activity and, therefore, GVL.Methods: Human NK cells were stimulated with IL‐15 in the presence of BM‐MSC or AT‐MSC. The effect of both MSC populations on NK cell proliferation, cell cycle progression, and CD56 expression was analyzed by flow cytometry. Cytokine secretion was measured by ELISA, and cytotoxic activity was assessed by calcein release assays.Results: Although both BM‐MSC and AT‐MSC induced a similar inhibition of NK cell proliferation, only BM‐MSC decreased significantly NK cell cytotoxic activity and showed a trend for a higher reduction of IFN‐γ secretion.Conclusion: These results suggest that, in the context of GVHD inhibition, the use of AT‐MSC rather than BM‐MSC could further preserve NK cell activity and, thus, favor GVL.
- 1 September 2015
- Published by Elsevier in International Immunopharmacology
- Vol. 28 (1) , 675-685
Comparative effect of two pan-class I PI3K inhibitors used as anticancer drugs on human T cell function
- 1 September 2015
- Published by Elsevier in International Immunopharmacology
- Vol. 28 (1) , 675-685
Comparative effect of two pan-class I PI3K inhibitors used as anticancer drugs on human T cell function
- 14 April 2015
- Published by Springer Nature in Immunologic Research
- Vol. 62 (2) , 175-188
Profound blockade of T cell activation requires concomitant inhibition of different class I PI3K isoforms
PI3K inhibitors have emerged as potential therapeutic tools for a variety of diseases, and thus, a vast array of compounds with specificity for different PI3K isoforms is being developed. Gaining knowledge about the contribution of the different isoforms to PI3K function will allow selecting the most appropriate inhibitor for each pathology. In this study, we have addressed the effect of PI3K inhibitors with specificity for different class I PI3K isoforms on primary human T cell activation. In particular, we have analyzed proliferation, expression of activation and differentiation markers, apoptosis induction, cytokine secretion and Akt phosphorylation in T cells stimulated in vitro with anti-CD3 and anti-CD28 monoclonal antibodies and cultured with either one of these compounds: p110β-specific inhibitor TGX-221, p110δ-specific inhibitor IC-87114, p110γ inhibitor AS-242525 or pan-class I PI3K inhibitor BKM120. Inhibition of any of the isoforms led to an impairment of T cell activation, mainly of cytokine secretion and granzyme B expression. However, only complete blockade of class I PI3K activity with the pan-class I inhibitor effectively abrogated T cell proliferation. These results indicate that these three p110 isoforms (β, δ and γ) take part in T cell activation, but all of them are dispensable for T cell proliferation.
- 14 April 2015
- Published by Springer Nature in Immunologic Research
- Vol. 62 (2) , 175-188
Profound blockade of T cell activation requires concomitant inhibition of different class I PI3K isoforms
PI3K inhibitors have emerged as potential therapeutic tools for a variety of diseases, and thus, a vast array of compounds with specificity for different PI3K isoforms is being developed. Gaining knowledge about the contribution of the different isoforms to PI3K function will allow selecting the most appropriate inhibitor for each pathology. In this study, we have addressed the effect of PI3K inhibitors with specificity for different class I PI3K isoforms on primary human T cell activation. In particular, we have analyzed proliferation, expression of activation and differentiation markers, apoptosis induction, cytokine secretion and Akt phosphorylation in T cells stimulated in vitro with anti-CD3 and anti-CD28 monoclonal antibodies and cultured with either one of these compounds: p110β-specific inhibitor TGX-221, p110δ-specific inhibitor IC-87114, p110γ inhibitor AS-242525 or pan-class I PI3K inhibitor BKM120. Inhibition of any of the isoforms led to an impairment of T cell activation, mainly of cytokine secretion and granzyme B expression. However, only complete blockade of class I PI3K activity with the pan-class I inhibitor effectively abrogated T cell proliferation. These results indicate that these three p110 isoforms (β, δ and γ) take part in T cell activation, but all of them are dispensable for T cell proliferation.
- 1 January 2009
- Published by Elsevier in Cytotherapy
- p. 1-8
Mesenchymal stem cells are functionally abnormal in patients with immune thrombocytopenic purpura
- 1 January 2009
- Published by Elsevier in Cytotherapy
- p. 1-8
Mesenchymal stem cells are functionally abnormal in patients with immune thrombocytopenic purpura